Ten years of HER2-directed therapy: Still questions after all these years

Breast Cancer Research and Treatment

Volumn 113, Issue 2, 2009, Pages 207-209

  Krop, Ian E ^a   Winer, Eric P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE DEACETYLASE INHIBITOR; LAPATINIB; TRASTUZUMAB;

BREAST CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HUMAN; NOTE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR RESISTANCE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; FORECASTING; HUMANS; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 58149231295     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0041-2     Document Type: Note

References (10)

1. DJ Slamon B Leyland-Jones S Shak 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792
2. EH Romond EA Perez J Bryant 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684
3. MJ Piccart-Gebhart M Procter B Leyland-Jones 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672
4. CE Geyer J Forster D Lindquist 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743
5. G von Minckwitz P Vogel M Schmidt 2007 Trastuzumab treatment beyond progression in patients with HER2-positive metastatic breast cancer the TBP study (GBG 26/BIG 3-05) Breast Cancer Res Treat 106 S185
6. E Antoine J Extra L Vincent-Salomon 2007 Multiple lines of trastuzumab provide a survival benefit for women with metastatic breast cancer: results from the Hermine cohort study Eur J Cancer Suppl 5 213 (Abstract 2099)
7. CE Geyer A Martin B Newstat 2007 Lapatinib plus capecitabine in HER2-positive advanced breast cancer: Genomic and updated efficacy data J Clin Oncol ASCO Annual Meeting Proceedings, Part I 25 1035
8. S Modi AT Stopeck MS Gordon 2007 Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER2 overexpressing breast cancer: a phase I dose-escalation study J Clin Oncol 25 5410 5417
9. H Burstein A Awada R Badwe 2007 HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 2 results in patients with advanced breast cancer Breast Cancer Res Treat 106 S268
10. IE Krop M Beeram S Modi 2007 A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2-positive breast cancer Breast Cancer Res Treat 106 S33